HIGHLIGHTS
- who: Qing Yang from the Jiangsu University, China have published the Article: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma, in the Journal: (JOURNAL)
- what: This study had a median followup period of 13 months.
- how: In this study apatinib and camrelizumab were used to treat HCC and tumor markers immune function and serum indexes were observed and analyzed to evaluate the safety and efficacy of the treatment regimen quantitatively.
SUMMARY
According to previous studies, molecular targeted therapy or chemotherapy combined . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.